Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 5-Week Trial To Assess The Efficacy And Safety Of PD 0332334 Compared To Placebo And Alprazolam Extended-Release In Patients With Generalized Anxiety Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2010
Price :
$35
*
At a glance
- Drugs Imagabalin (Primary) ; Alprazolam
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Pfizer
- 17 Jun 2009 New trial record